Enterprise record
Amylyx Pharmaceuticals, Inc.
Public governance Claims and source records for this enterprise.
Follow
More
Alpha ID: alpha:company:ff2d5a37-e808-42b8-ac38-9a58a3e11cfaVersion: public-1As of: unavailable
10 published Claims2 sources
Key Claims
Board and committees
Evidence, history and coverage
Additional published Claims
Published evidence records
2 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.
Alpha canonical company public projection
canonical identity · Source published: Date unavailable · Retrieved: Sep 28, 2026
Supports 3 claims
- Legal Name: Amylyx Pharmaceuticals, Inc. · Claim reviewed: Sep 28, 2026
- Entity Status: Public listing published · Claim reviewed: Sep 28, 2026
- Published Fact: US · Claim reviewed: Sep 28, 2026
Amylyx Pharmaceuticals, Inc. DEF 14A 2026-04-23
sec proxy · Source published: Apr 23, 2026 · Retrieved: Apr 24, 2026
Supports 7 claims
- Leadership Role: Bernhardt Zeiher, M.D.: Director · Claim reviewed: Sep 28, 2026
- Leadership Role: Daphne Quimi: Director · Claim reviewed: Sep 28, 2026
- Leadership Role: George Mclean Milne Jr., Ph.D.: Director · Claim reviewed: Sep 28, 2026
- Leadership Role: Joshua Cohen: Director · Claim reviewed: Sep 28, 2026
- Leadership Role: Justin Klee: Director · Claim reviewed: Sep 28, 2026
- Leadership Role: Karen Firestone: Director · Claim reviewed: Sep 28, 2026
- Leadership Role: Paul Fonteyne: Director · Claim reviewed: Sep 28, 2026
No published record changes are available in this projection.
Identity
unclaimed
Evidence
source reported
Evaluation
Unknown
Monitoring
Unknown
Authority
Unknown
Freshness
Observed 2026-09-28
- Board and committees
- published
- Control and shareholders
- not observed
- Compensation
- not observed
- Auditors, advisors and reporting
- not observed
- Legal
- not observed
- AI governance
- not observed

